Press Room

News / Nov 29, 2021

Hovione distinguished with the Order of Engineers trophy

Mrs. Diane Villax represented Hovione at the Gala of the Order of Engineers

Diane Villax receives Order of Engineers trophy | Hovione

In the picture: Herman José, presenter of the ceremony, Diane Villax, founder chairman of Hovione, António Gonçalves da Silva, President of the College of Chemical and Biological Engineering.

 
 

The Order of Engineers (OE) in Portugal celebrated its 85th anniversary and to mark the occasion held a Gala on the 27th of November. During the ceremony, OE trophies were awarded to distinguish the best projects, works, personalities or institutions of National Engineering.

Hovione was awarded for its work in the field of pharmaceutical chemistry over more than 60 years.

The award was received by Mrs. Diane Villax on behalf of Hovione. In her acceptance speech, Mrs. Diane Villax referred to Hovione's role in research and development, highlighting the important contribution given by the Team members and the PhD’s and Master programs in progress within the company.

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026